Loading...
Reach Banner
Keywords
Last name
Institution

Connection

Co-Authors

This is a "connection" page, showing publications co-authored by Ingrid Tein and Anne-Marie LamHonWah.

 
Connection Strength
 
 
 
6.751
 
  1. Lamhonwah AM, Tein I. Expression of the organic cation/carnitine transporter family (Octn1,-2 and-3) in mdx muscle and heart: Implications for early carnitine therapy in Duchenne muscular dystrophy to improve cellular carnitine homeostasis. Clin Chim Acta. 2020 Jun; 505:92-97.
    View in: PubMed
    Score: 0.947
  2. Lamhonwah AM, Baric I, Lamhonwah J, Grubic M, Tein I. Attention deficit/hyperactivity disorder as an associated feature in OCTN2 deficiency with novel deletion (p.T440-Y449). Clin Case Rep. 2018 04; 6(4):585-591.
    View in: PubMed
    Score: 0.824
  3. Lamhonwah AM, Mai L, Chung C, Lamhonwah D, Ackerley C, Tein I. Upregulation of mammary gland OCTNs maintains carnitine homeostasis in suckling infants. Biochem Biophys Res Commun. 2011 Jan 28; 404(4):1010-5.
    View in: PubMed
    Score: 0.503
  4. Lamhonwah AM, Bear CE, Huan LJ, Kim Chiaw P, Ackerley CA, Tein I. Cystic fibrosis transmembrane conductance regulator in human muscle: Dysfunction causes abnormal metabolic recovery in exercise. Ann Neurol. 2010 Jun; 67(6):802-8.
    View in: PubMed
    Score: 0.483
  5. Lamhonwah AM, Wong J, Tam C, Mai L, Tein I. Organic cation/carnitine transporter family expression patterns in adult murine heart. Pathol Res Pract. 2009; 205(6):395-402.
    View in: PubMed
    Score: 0.443
  6. Lamhonwah AM, Hawkins CE, Tam C, Wong J, Mai L, Tein I. Expression patterns of the organic cation/carnitine transporter family in adult murine brain. Brain Dev. 2008 Jan; 30(1):31-42.
    View in: PubMed
    Score: 0.394
  7. Lamhonwah AM, Tein I. Novel localization of OCTN1, an organic cation/carnitine transporter, to mammalian mitochondria. Biochem Biophys Res Commun. 2006 Jul 14; 345(4):1315-25.
    View in: PubMed
    Score: 0.365
  8. Lamhonwah AM, Ackerley CA, Tilups A, Edwards VD, Wanders RJ, Tein I. OCTN3 is a mammalian peroxisomal membrane carnitine transporter. Biochem Biophys Res Commun. 2005 Dec 30; 338(4):1966-72.
    View in: PubMed
    Score: 0.352
  9. Lamhonwah AM, Ackerley C, Onizuka R, Tilups A, Lamhonwah D, Chung C, Tao KS, Tellier R, Tein I. Epitope shared by functional variant of organic cation/carnitine transporter, OCTN1, Campylobacter jejuni and Mycobacterium paratuberculosis may underlie susceptibility to Crohn's disease at 5q31. Biochem Biophys Res Commun. 2005 Dec 02; 337(4):1165-75.
    View in: PubMed
    Score: 0.350
  10. Lamhonwah AM, Onizuka R, Olpin SE, Muntoni F, Tein I. OCTN2 mutation (R254X) found in Saudi Arabian kindred: recurrent mutation or ancient founder mutation? J Inherit Metab Dis. 2004; 27(4):473-6.
    View in: PubMed
    Score: 0.310
  11. Lamhonwah AM, Skaug J, Scherer SW, Tein I. A third human carnitine/organic cation transporter (OCTN3) as a candidate for the 5q31 Crohn's disease locus (IBD5). Biochem Biophys Res Commun. 2003 Jan 31; 301(1):98-101.
    View in: PubMed
    Score: 0.291
  12. Lamhonwah AM, Olpin SE, Pollitt RJ, Vianey-Saban C, Divry P, Guffon N, Besley GT, Onizuka R, De Meirleir LJ, Cvitanovic-Sojat L, Baric I, Dionisi-Vici C, Fumic K, Maradin M, Tein I. Novel OCTN2 mutations: no genotype-phenotype correlations: early carnitine therapy prevents cardiomyopathy. Am J Med Genet. 2002 Aug 15; 111(3):271-84.
    View in: PubMed
    Score: 0.282
  13. Lamhonwah AM, Tein I. GFP-Human high-affinity carnitine transporter OCTN2 protein: subcellular localization and functional restoration of carnitine uptake in mutant cell lines with the carnitine transporter defect. Biochem Biophys Res Commun. 1999 Nov 02; 264(3):909-14.
    View in: PubMed
    Score: 0.232
  14. Lamhonwah AM, Tein I. Carnitine uptake defect: frameshift mutations in the human plasmalemmal carnitine transporter gene. Biochem Biophys Res Commun. 1998 Nov 18; 252(2):396-401.
    View in: PubMed
    Score: 0.217
  15. Nabavi Nouri M, Lamhonwah AM, Tein I. Novel myophosphorylase mutation (p.Arg94Pro) with progressive exercise intolerance. Clin Case Rep. 2018 03; 6(3):499-501.
    View in: PubMed
    Score: 0.205
  16. Zolkipli Z, Mai L, Lamhonwah AM, Tein I. The mdx mouse as a model for carnitine deficiency in the pathogenesis of Duchenne muscular dystrophy. Muscle Nerve. 2012 Nov; 46(5):767-72.
    View in: PubMed
    Score: 0.143
  17. Zolkipli Z, Pedersen CB, Lamhonwah AM, Gregersen N, Tein I. Vulnerability to oxidative stress in vitro in pathophysiology of mitochondrial short-chain acyl-CoA dehydrogenase deficiency: response to antioxidants. PLoS One. 2011 Apr 01; 6(4):e17534.
    View in: PubMed
    Score: 0.128
  18. Tein I, Elpeleg O, Ben-Zeev B, Korman SH, Lossos A, Lev D, Lerman-Sagie T, Leshinsky-Silver E, Vockley J, Berry GT, Lamhonwah AM, Matern D, Roe CR, Gregersen N. Short-chain acyl-CoA dehydrogenase gene mutation (c.319C>T) presents with clinical heterogeneity and is candidate founder mutation in individuals of Ashkenazi Jewish origin. Mol Genet Metab. 2008 Feb; 93(2):179-89.
    View in: PubMed
    Score: 0.102
  19. Xuan W, Lamhonwah AM, Librach C, Jarvi K, Tein I. Characterization of organic cation/carnitine transporter family in human sperm. Biochem Biophys Res Commun. 2003 Jun 20; 306(1):121-8.
    View in: PubMed
    Score: 0.075
  20. Verbeeten KC, Lamhonwah AM, Bulman D, Faghfoury H, Chakraborty P, Tein I, Geraghty MT. Carnitine uptake defect due to a 5'UTR mutation in a pedigree with false positives and false negatives on Newborn screening. Mol Genet Metab. 2020 03; 129(3):213-218.
    View in: PubMed
    Score: 0.058
  21. Tkachyova I, Fan X, LamHonWah AM, Fedyshyn B, Tein I, Mahuran DJ, Schulze A. NDST1 Preferred Promoter Confirmation and Identification of Corresponding Transcriptional Inhibitors as Substrate Reduction Agents for Multiple Mucopolysaccharidosis Disorders. PLoS One. 2016; 11(9):e0162145.
    View in: PubMed
    Score: 0.047
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.